A
References
Abe, S. 2013. Japan’s strategy for global health diplomacy: Why it matters. Lancet 382(9896):915-916.
Adebamowo, C., O. Bah-Sow, F. Binka, R. Bruzzone, A. Caplan, J. F. Delfraissy, D. Heymann, P. Horby, P. Kaleebu, J. J. Tamfum, P. Olliaro, P. Piot, A. Tejan-Cole, O. Tomori, A. Toure, E. Torreele, and J. Whitehead. 2014. Randomised controlled trials for Ebola: Practical and ethical issues. Lancet 384:1423-1424.
Bhan, M. K., R. I. Glass, K. M. Ella, N. Bhandari, J. Boslego, H. B. Greenberg, K. Mohan, G. Curlin, and T. S. Rao. 2014. Team science and the creation of a novel rotavirus vaccine in India: A new framework for vaccine development. Lancet 383(9935):2180-2183.
Bhandari, N., T. Rongsen-Chandola, A. Bavdekar, J. John, K. Antony, S. Taneja, N. Goyal, A. Kawade, G. Kang, S. S. Rathore, S. Juvekar, J. Muliyil, A. Arya, H. Shaikh, V. Abraham, S. Vrati, M. Proschan, R. Kohberger, G. Thiry, R. Glass, H. B. Greenberg, G. Curlin, K. Mohan, G. V. Harshavardhan, S. Prasad, T. S. Rao, J. Boslego, M. K. Bhan, and the India Rotavirus Vaccine Group. 2014. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: A randomised, double-blind, placebo-controlled trial. Lancet 383(9935):2136-2143.
Borio, L., E. Cox, and N. Lurie. 2015. Combating emerging threats—accelerating the availability of medical therapies. New England Journal of Medicine 373(11):993-995.
Cox, E., L. Borio, and R. Temple. 2014. Evaluating Ebola therapies—the case for RCTs. New England Journal of Medicine 371(25):2350-2351.
De Gregorio, E., and R. Rappuoli. 2014. From empiricism to rational design: A personal perspective of the evolution of vaccine development. Nature Reviews Immunology 14(7):505-514.
Fineberg, H. V. 2015. Pandemic preparedness and response—lessons from the H1N1 influenza of 2009. In Emerging viral diseases: The One Health connection: Workshop summary. Washington, DC: The National Academies Press. Pp. 152-165.
IOM (Institute of Medicine). 2015a. Rapid medical countermeasure response to infectious diseases: Enabling sustainable capabilities through ongoing public- and private-sector partnerships: Workshop summary. Washington, DC: The National Academies Press.
IOM. 2015b. Sharing clinical trial data: Maximizing benefits, minimizing risk. Washington, DC: The National Academies Press.
Jaffe, K., M. Caicedo, M. Manzanares, M. Gil, A. Rios, A. Florez, C. Montoreano, and V. Davila. 2013. Productivity in physical and chemical science predicts the future economic growth of developing countries better than other popular indices. PLoS ONE 8(6):e66239.
Levine, M. M., M. Tapia, A. V. Hill, and S. O. Sow. 2015. How the current West African Ebola virus disease epidemic is altering views on the need for vaccines and is galvanizing a global effort to field-test leading candidate vaccines. Journal of Infectious Diseases 211(4):504-507.
Pedrique, B., N. Strub-Wourgaft, C. Some, P. Olliaro, P. Trouiller, N. Ford, B. Pécoul, and J. H. Bradol. 2013. The drug and vaccine landscape for neglected diseases (2000-11): A systematic assessment. Lancet Global Health 1(6):e371-e379.
Plotkin, S. A., A. A. Mahmoud, and J. Farrar. 2015. Establishing a global vaccine-development fund. New England Journal of Medicine 373(4):297-300.